REGN vs. WAT: Regeneron Pharmaceuticals vs. Waters Stock Comparison

November 11, 2026

How do Regeneron Pharmaceuticals (REGN) and Waters (WAT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Regeneron Pharmaceuticals (REGN) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but REGN is classified in Biotechnology while WAT is classified in Life Sciences Tools & Services.

Company profile comparison for Regeneron Pharmaceuticals (REGN) and Waters (WAT)
Profile Item	REGN	WAT
Name	Regeneron Pharmaceuticals, Inc.	Waters Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	93.55 billion USD	44.93 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	April 2, 1991	November 17, 1995
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

REGN

WAT

GSPC

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Regeneron Pharmaceuticals (REGN) and Waters (WAT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Regeneron Pharmaceuticals (REGN) and Waters (WAT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Regeneron Pharmaceuticals (REGN) and Waters (WAT)
Metric	REGN	WAT
Total Return (1Y)	40.87%	27.70%
Total Return (3Y, Annualized)	5.15%	23.32%
Total Return (5Y, Annualized)	8.58%	6.27%

Risk Profile

Drawdown History

REGN

WAT

GSPC

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Regeneron Pharmaceuticals (REGN) and Waters (WAT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Regeneron Pharmaceuticals (REGN) and Waters (WAT)
Metric	REGN	WAT
Volatility (1Y, Annualized)	34.08%	35.45%
Beta (5Y)	0.10	1.13
Max Drawdown (5Y)	-59.69%	-36.47%
Avg. Volume (3M)	772.95K	816.72K

Risk-Adjusted Performance

Risk-Return Positioning

REGN and WAT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Regeneron Pharmaceuticals (REGN) and Waters (WAT)
Metric	REGN	WAT
Sharpe Ratio (1Y)	1.07	0.66
Sortino Ratio (1Y)	1.70	0.98

Profitability

ROE (TTM)

Regeneron Pharmaceuticals (REGN) at 14.95% sits in the top ROE quartile, while Waters (WAT) at 1.12% is closer to the peer norm — stronger capital efficiency for REGN.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.95%

Max: 109.18%
REGN: 14.95%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12%

Max: 109.18%
Q3: 6.23%
WAT: 1.12%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Regeneron Pharmaceuticals (REGN) at 28.51% converts revenue to bottom-line profit above its industry’s benchmark range, while Waters (WAT) at 1.76% keeps roughly the typical share for its industry.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.51%

REGN: 28.51%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.76%

Max: 18.05%
Q3: 4.78%
WAT: 1.76%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Regeneron Pharmaceuticals (REGN) at 40.46% operates in the top operating margin quartile, ahead of Waters (WAT) at 11.38%, which runs around its industry’s norm.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.46%

Max: 83.12%
REGN: 40.46%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.38%

Max: 83.12%
Q3: 14.77%
WAT: 11.38%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Regeneron Pharmaceuticals (REGN) and Waters (WAT)
Metric	REGN	WAT
ROE (TTM)	14.95%	1.12%
ROA (TTM)	7.59%	2.36%
Net Margin (TTM)	28.51%	1.76%
Operating Margin (TTM)	40.46%	11.38%
Gross Margin (TTM)	46.73%	49.83%

Growth

Revenue Growth

Both Regeneron Pharmaceuticals (REGN) at 0.99% and Waters (WAT) at 6.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Regeneron Pharmaceuticals (REGN) at 8.19% and Waters (WAT) at 0.47% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Regeneron Pharmaceuticals (REGN) and Waters (WAT)
Metric	REGN	WAT
Revenue Growth (YoY)	0.99%	6.99%
Revenue Growth (3Y CAGR)	5.62%	2.12%
EPS Growth (YoY)	8.19%	0.47%
EPS Growth (3Y CAGR)	2.77%	-2.84%

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Regeneron Pharmaceuticals (REGN) shows current ratio of 3.35 against its industry benchmark, while Waters (WAT) has no reading this period.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.35

Max: 25.13
Q3: 12.13
Median: 5.52
REGN: 3.35
Q1: 2.47
Min: 0.10

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10
WAT: --

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): WAT does not report current ratio, so it has no value marker; REGN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

Both Regeneron Pharmaceuticals (REGN) at 0.08 and Waters (WAT) at 0.34 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.08

Max: 1.42
Q3: 0.65
Median: 0.15
REGN: 0.08
Q1: 0.02
Min: 0.00

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.34

Max: 1.42
Q3: 0.65
WAT: 0.34
Median: 0.15
Q1: 0.02
Min: 0.00

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Regeneron Pharmaceuticals (REGN) and Waters (WAT)
Metric	REGN	WAT
Current Ratio (MRQ)	3.35	--
Debt / Equity (MRQ)	0.08	0.34
Net Debt / EBITDA	-1.17	3.23

Dividends

Dividend Yield (TTM)

Waters (WAT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41%

REGN: 0.41%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

WAT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Waters (WAT) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.18%

REGN: 8.18%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

WAT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Regeneron Pharmaceuticals (REGN) and Waters (WAT)
Metric	REGN	WAT
Dividend Yield (TTM)	0.41%	0.00%
Dividend Payout Ratio (TTM)	8.18%	0.00%

Valuation

P/E Ratio (TTM)

Regeneron Pharmaceuticals (REGN) at 19.99 is near its industry’s usual P/E ratio, while Waters (WAT) at 191.46 sits above its peer range — an unusually expensive price for WAT’s trailing earnings.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.99

Max: 85.34
Q3: 43.46
Median: 26.69
REGN: 19.99
Q1: 13.30
Min: 0.07

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

191.46

WAT: 191.46
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Regeneron Pharmaceuticals (REGN) at 5.54 and Waters (WAT) at 8.01 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.54

Max: 58.18
Q3: 25.77
Median: 7.30
REGN: 5.54
Q1: 3.01
Min: 0.01

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.01

Max: 58.18
Q3: 25.77
WAT: 8.01
Median: 7.30
Q1: 3.01
Min: 0.01

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Regeneron Pharmaceuticals (REGN) at 2.71 and Waters (WAT) at 2.94 are valued close to their industries’ norm against book — neither stands out from peers.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.71

Max: 13.53
Q3: 6.54
Median: 3.25
REGN: 2.71
Q1: 1.69
Min: -5.59

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.94

Max: 13.53
Q3: 6.54
Median: 3.25
WAT: 2.94
Q1: 1.69
Min: -5.59

Regeneron Pharmaceuticals (REGN) vs. Waters (WAT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Regeneron Pharmaceuticals (REGN) and Waters (WAT)
Metric	REGN	WAT
P/E Ratio (TTM)	19.99	191.46
P/S Ratio (TTM)	5.54	8.01
P/B Ratio (MRQ)	2.71	2.94
Free Cash Flow Yield (TTM)	2.76%	--